Question 1

How does EquitAI evaluate Genmab A/S's (GMAB) valuation and Stock DNA?

Accepted Answer

Genmab A/S (GMAB) trades at $57.06 with an EquitAI Valuation DNA score of 2/10 and Quality score of 9/10. The company's trailing P/E ratio is 45.6x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does Genmab A/S (GMAB) operate in?

Accepted Answer

Genmab A/S (GMAB) is classified under the Healthcare sector within the Biotechnology industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Biotechnology peers and broader Healthcare market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for Genmab A/S (GMAB)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $50.6 for Genmab A/S (GMAB), representing an implied 11.3% downside from its current trading level of $57.06 with an average rating of Buy based on 4 analyst ratings. Individual analyst price targets range from a low of $40.0 to a high of $70.0, with a median forecast of $43.0. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does GMAB pay dividends or capital distributions?

Accepted Answer

Genmab A/S does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

Question 5

Who are Genmab A/S's (GMAB) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include MGNX, XNCR, CGEN, IPHA. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's GMAB analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

GMAB - Genmab A/S Stock Analysis & Valuation

Genmab A/S

FIT ANALYSIS